Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5382_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
17 Мб
Скачать
☆
(a)
56.6 cm
(b)
Reagent and
gas-handling robot
Dispoable cassettes
Reactors
Figure 13.7 ELIXYS
hybrid synthesizer.
Source: (a) Lazari, M., Quinn, K.M., Claggett, S.B. et al., [33]. Under a
creative Commons License (https:// creativecommons. org/licenses/by/
2.0/).
(c)
37.3 cm
63.2 cm
the same module. The only changes between syntheses are the reagents, program, and purication cartridges, as well as a small number of connections between the cassettes. The ELIXYS module also provides access to the reaction vessel, giving the radiochemist
the ability to take intermediate measurements while eliminating the need for large num-
bers of valves: the decreased number of ttings and valves increases module reliability.
These features enable the production and development of multiple syntheses in a single
system and hot cell, thus requiring less space in smaller lab settings.
The ELIXYS FLEX/CHEM allows for automation without operator intervention up to the nal purication step, as this module does not support integrated HPLC purication and formulation; this can, however, be automated by incorporating a separate ELIXYS PURE/FORM module. Cleaning of this latter system is necessary unless disposable cas­settes are used as intended. In a recent report, Collins’ etal. used ELIXYS FLEX/CHEM to produce 24 dierent
18
F-labeled radiopharmaceuticals and prosthetic groups, showcasing
the utility of the hybrid synthesis module in the eld[4]. A hybrid system such as ELIXYS therefore has great utility for laboratories that perhaps just have space and/or funding
for a single synthesis module but want to be able to conduct both routine production of
established radiopharmaceuticals and development of new radiotracers.
Chapter 13: Automated Synthesis Modules for PET Radiochemistry 445

13.6 MICROFLUIDIC SYSTEMS

(a)
Many of the traditional radiochemistry synthesis modules described in this chapter use a
single uid bus architecture in conjunction with stopcock valve manifold(s), in which every uid runs through parts of the central pathway, and many have been designed for the express purpose of manufacturing [ a more exible radiopharmaceutical synthesis platform that is compatible with dierent
levels of radioactivity (single dose-on-demand production or multidose batches) as well
as a variety of radionuclides and/or radiopharmaceuticals, and that can t into the space connes of a typical radiochemistry laboratory with only one or two hot cells. In addition to the xed-tubing modules described in this chapter, signicant work has also been undertaken to develop microuidic approaches for radiopharmaceutical manufacturing (for recent examples, see[36–84]), as well as purication/reformulation[85]. Microuidic devices have been used to manufacture radiopharmaceuticals for clinical use[86–89],
but continuing challenges have limited their commercialization and transition into
widespread use[90]. The reasons for the slow uptake are numerous and depend on the particular application, but include (i) cost, (ii) the lack of aordable components due to
dependence on specialized chips, and (iii) challenges with the macro-to-micro interface
(incompatibility between microuidic volumes [≤ 0.05 ml] and the typical “large-scale” volumes used in cyclotrons and radiopharmaceutical dosing [≥ 10 ml]). Modules that have been commercialized include the Advion NanoTek (Figure13.8a), used for both PET radiochemistry[91, 92] and standard organic synthesis[93], as well as ABTs BG75 (Figure13.8b)[38]. Most recently, we have collaborated with GE to introduce ISAR[94]. The ISAR system (Figure13.8c) oers parallel uidics that overcomes the single uid bus
and associated challenges at the macro-to-micro interface by marrying standard volumes
and techniques and o-the-shelf components for radiopharmaceutical synthesis with the established benets of a microreactor setup; this system oers a promising approach for the automated production of radiopharmaceuticals in the future.
18
F]FDG. However, as stated earlier, there is a need for
(b) (c)
(a)
(c) (d)
Figure 13.8 (a) Advion NanoTek. Source: Reproduced from Palmieri etal. 2009 with permission from
Elsevier. (b) ABT BG75. Source: Reproduced from Awasthi etal. 2014 with permission from Else­vier. (c) ISAR. Source: Reproduced from Frank etal. 2019 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0).
(b)
446 Handbook of Radiopharmaceuticals
13.7   SYNTHESIS MODULES FORUSE 
WITHSOLID TARGETS
The increased use of longer-lived PET radionuclides has led to eorts to commercialize methods for their production. Smaller amounts of such radionuclides can be prepared on cyclotrons using liquid targets[95], but large-scale production requires the use of solid targets[96]. Initial solid-target work involved the use of homemade systems, and such systems continue to be reported[97–99], but moving solid targetry from the
research arena to a point where it can be used for daily routine production has necessi-
tated the development of dedicated commercially available solutions. These systems
usually include the solid targetry, a shuttle method to move the solid target to and from the cyclotron, and a module for the chemistry steps needed to dissolve the solid target and convert the radionuclide to a useable form for subsequent radiochemical syntheses, in the same module or one of the other synthesis modules already described in this
chapter. For example, the ALCEO solid target system has been developed by Comecer (Figure13.9), while IBA introduced Nirta, and ARTMS also oers a solid target system. Both the ALCEO and Nirta systems require electrodeposition steps to manufacture the
(a)
Electrodeposition of
the
enriched
Dissolution of
Shuttle storage Electrochemical cell
Shuttle delivery pipe
(b) (d)
Irradiation Cooling
PTS
64
irradiated
target
(c)EDS PRF
Ni
64
Cu product capillary
Final preparation
Reservoirs Ion exchange Purication
TA DDEO
Figure 13.9
Modular setup of the ALCEO system. The shuttle is trans­ported between the EDS (a) and PTS (b) via a delivery pipe; the EDS (a) and PRF (c) are connected by cap­illaries to enable
the circulating uid
transport; and the
nal product is
transferred from the PRF (c) through capillaries to the Taddeo module (d)
for nal processing.
Source: Repro­duced from Fiedler etal. 2018 with per­mission from John Wiley and Sons.
Chapter 13: Automated Synthesis Modules for PET Radiochemistry 447
actual target, while ARTMS targets are commercially available. These solid target sys­tems have been developed for cyclotron production of
64
Cu, 68Ga, 86Y, 89Zr,
123
I, and
124
I,
etc., and reports on such systems discuss their installation and use in the eld[100, 101].
For example, the production of
64
Cu using ALCEO was described by Fiedler[100]. ALCEO is
composed of a number of dierent modules for electrodeposition, dissolution, transfer,
and storage of targets (EDS), an irradiation unit (PTS) connected to the cyclotron, a puri-
cation module (PRF) and a synthesis module (Taddeo). The enriched material is depos­ited on the target by the EDS and shuttled to the PTS on the cyclotron for irradiation. Once irradiation has occurred, the EDS shuttles the target back to the laboratory and dissolves the target. The radionuclide is then sent through capillary lines to the PRF for purication and, nally, Comecer’s Taddeo synthesis module for radiochemistry. With the
rapid uptick in use of growth in use of both
68
Ga radiopharmaceuticals for clinical studies recently, and steady
68
Ga and 89Zr use for immuno-PET (for recent reviews, see[102,
103]), the growth in use of these solid-target systems for production and handling of such radioactive metal ions is expected to continue in the future.

13.8  AUTOMATED QUALITY CONTROL TESTING

In addition to advances and automation in synthesis modules, a similar push has been made to automate quality control testing of PET radiopharmaceuticals[104–106]. In
order for a dose to be released for clinical use, it must pass a battery of quality con-
trol tests such as radiochemical and chemical purity (HPLC and TLC), residual solvent levels gas chromatography (GC), visual inspection, pH, osmolarity, radionuclidic identity (half-life), purity, sterile lter integrity, bacterial endotoxin levels, and sterility. These
tests generally use separate pieces of analytical equipment, which are expensive to pur-
chase and maintain. To reduce waste and reduce lab space requirements, a push for auto­mation has led to the design of miniaturized systems such as the Tracer-QC (Figure13.10) and QC1 that can incorporate all of these tests into a single unit. The concept is beyond the scope of this chapter, as it is discussed at length in Chapter14.
13.9  CONCLUSIONS ANDFUTURE DIRECTIONS
Radiochemistry modules have come a long way from the early systems of the 1980s, with a number of advanced systems now commercially available for dierent radionuclides and a wide range of applications. The increased demand for PET radiopharmaceuticals
has led to the development of cassette-based modules that are compliant with cGMP and capable of handling multiple curies of radioactivity, while a continuing need to develop
novel radiopharmaceuticals and/or new radiosynthesis methods has also led to the evo­lution of more exible xed-tube synthesis modules and systems for working with solid targetry. For labs that have limited hot-cell space available, hybrid systems that use cassettes capable of both routine cassette-based production and exibility have been recently introduced. This is the current state of the art at the time of writing. However,
448 Handbook of Radiopharmaceuticals
Figure 13.10
Tracer-QC automated QC
module. Source: Image courtesy of LabLogic and
Trac e - A b i lity,
Inc. Other man­ufacturers of
automated QC
equipment
include QC1.
there remains a desire to reduce the cost and scale of PET radiosyntheses through the
use of microuidics. To this end, the rst microuidic systems for radiosynthesis, refor­mulation, and automation of quality control have been commercialized since the rst
edition of the Handbook of Radiopharmaceuticals.
The next generation of PET radiochemistry equipment is beginning to be conceived,
with two new approaches emerging. The rst of these considers the need for rapid and exible production of new components for automation of new radiochemistry and/or synthesis of novel PET radiotracers, and capitalizes on recent developments in 3-dimen­sional (3D) printing technologies to translate optimized reaction conditions into synthesis modules and components composed of 3D-printed, electronic, and robotic parts[107].
The second development imagines a future of cGMP PET radiopharmaceutical produc-
tion that is one of full automation, with little to no interaction by radiochemists. With the increasing connection of PET equipment to the Internet of Things (for more thoughts on PET radiochemistry and the Internet of Things, see[108]), it is possible that in the
future, the various systems described in this chapter could communicate with each other to check inventory, order supplies, and ensure the suitability of the cyclotron, synthesis
modules, and quality control equipment for use. The synthesis could potentially be set up
the day before, and the entire process could be remote-activated so the dose was ready
when the radiochemists arrived. Notications of the synthesis could also be sent to the
radiochemists, keeping them up to date on its progress as well as warning them of any
Chapter 13: Automated Synthesis Modules for PET Radiochemistry 449
problems, and articial intelligence (AI) could be used to track, trend, and troubleshoot the big data logged from every radiosynthesis to improve eciency and reduce the cost of radiopharmaceutical manufacture in the future. The features to enable these advances are becoming available on today’s equipment, and it will be exciting to see how the tech­nology develops next.

REFERENCES

1. Vavere, A.L. and Scott, P.J.H. (2017). Clinical applications of small-molecule PET radiotracers: current progress and future outlook. Semin. Nucl. Med. 47 (5): 429–453.
2. PET Imaging Market Summary Report 2018. https://imvinfo.com/product/2020-pet­imaging-market-summary-report.
3. Eberl, S., Eriksson, T., Svedberg, O. etal. (2012). High beam current operation of a
PETtrace™ cyclotron for
4. Collins, J., Waldmann, C.M., Drake, C. etal. (2017). Production of diverse PET probes with limited resources: 24 sizer. Proc. Natl. Acad. Sci. U.S.A. 114: 11309 –11314 .
5. Li, S., Schmitz, A., Lee, H., and Mach, R.H. (2016). Automation of the radiosynthe­sis of six dierent Chem. 1: 15.
6. Shao, X., Hoareau, R., Hockley, B.G. etal. (2011). Highlighting the versatility of the tracerlab synthesis modules. Part 1: Fully automated production of [ radiopharmaceuticals using a Tracerlab FX 54: 292–307.
7. Shao, X., Hoareau, R., Runkle, A.C. etal. (2011b). Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [ radiopharmaceuticals using a Tracerlab FXC-Pro. J. Labelled Compd. Radiopharm. 54: 819–838.
8. Krasikova, R. (2007). Synthesis modules and automation in F-18 labeling. In: PET Chemistry, Ernst Schering Research Foundation Workshop, vol. 62 (eds. P.A. Schubiger, L. Lehmann and M. Friebe), 289–316.
9. Boschi, S., Lodi, F., Malizia, C. etal. (2013). Automation synthesis modules review. Appl. Radiat. Isot. 76: 38–45.
10. Claggett, S.B., Quinn, K.M., Lazari, M. etal. (2013). Simplied programming and con­trol of automated radiosynthesizers through unit operations. EJNMMI Res. 3: 53.
11. Welch, M.J., Dence, C.S., Marshall, D.R., and Kilbourn, M.R. (1983). Remote system for production of Carbon-11 labeled Palmitic acid. J. Labelled Compd. Radiopharm. 20: 1087–1095.
12. Brodack, J.W., Kilbourn, M.R., Welch, M.J., and Katzenellenbogen, J. (1988).
Automated production of several positron-emitting radiopharmaceuticals using a
single laboratory robot. Appl. Radiat. Isot. 39: 689–698.
13. Yu, S. (2006). Review of vention J. 2: e57.
18F−
production. Appl. Radiat. Isot. 70: 922–930.
18
F-labeled compounds prepared with a single radiosynthe-
18
F-labeled radiotracers on the AllinOne. EJNMMI Radiopharm.
18
F]labelled
. J. Labelled Compd. Radiopharm.
FN
11
C]-labeled
18
F-FDG synthesis and quality control. Biomed. Imaging Inter-
450 Handbook of Radiopharmaceuticals
14. MJH Life Sciences. 2001. GE plans acquisition of PET device maker Coincidence Tech­nologies. www.diagnosticimaging.com/ge/ge-plans-acquisition-pet-device-maker­coincidence-technologies, accessed 13 Sept 2018.
15. Oh, S.J., Chi, D.Y., Mosdzianowski, C. etal. (2005). Fully automated synthesis of [ uoromisonidazole using a conventional [
16. Kryza, D., Tadino, V., Filannino, M.A. etal. (2008). Fully automated [
18
F]FDG module. Nucl. Med. Biol. 32: 899–905.
18
F]uorocho-
18
F]
line synthesis in the TracerLab MX FDG coincidence synthesizer. Nucl. Med. Biol. 35: 255–260.
17. Cardinale, J., Martin, R., Remde, Y. etal. Procedures for the GMP-compliant produc­tion and quality control of [
18
F]PSMA-1007: a next generation radiouorinated tracer
for the detection of prostate cancer. Pharmaceuticals (Basel) 10: E77.
18. Neels, O., Martin, R., Cardinale, J. etal. (2018). GMP-compliant fully automated sin­gle-step radiosynthesis of [
18
F]PSMA-1007 using SPE cartridge purication. J. Nucl.
Med. 59 (Suppl. 1): 402.
19. Huang, Y.-Y., Tsai, C.-L., Chang, Y.-N., and Yan, R.-F. (2017). Automated production of
GMP-compliant
18
F-FES as an estrogen receptor ligand for breast cancer imaging.
Ann. Nucl. Med. Mol. Imaging 30: 143–250.
20. Prata, M.I. (2012). Gallium-68: a new trend in radiopharmacy. Curr. Radiopharm. 5: 142–149.
21. Jayavarapu, R., Waits, T., Chauhan, A. etal. (2018). Our initial experience with
68
Ga-
DOTATATE in the USA clinical dimension: added value in management decision mak­ing. J. Nucl. Med. 59 (Suppl. 1): 1225.
22. Nurmi, J. (2016). Leimausolosuhteiden optimointi
68
Ga-DOTA- NOC-leimauksessa GE TRACERlab MX-synteesilaitteella. E-thesis, Metropolia Ammattikorkeak­oulu. https://www.theseus./bitstream/handle/10024/147310/Nurmi_Jenni. pdf?sequence=1&isAllowed=y, accessed 5 August 2019.
23. Haka, M., Walsh, J., and Webster, E. (2017). P450: cleaning validation concepts for commercial radiopharmaceutical manufacturing. J. Labelled Compd. Radiopharm. 60 (Suppl. 1): S632.
24. Sowa, A.R., Jackson, I.M., Desmond, T.J. etal. (2018). Futureproong [
18
F]Fludeoxyglu-
cose manufacture at an Academic Medical Center. EJNMMI Radiopharm. Chem. 3 (1): 12.
25. Rodnick, M., Hockley, B., Piert, M. etal. (2019). P149 -- clinical implementation of cyclotron-based [
68
Ga]Ga-PSMA-11 at the University of Michigan. J. Labelled Compd.
Radiopharm. 62 (Suppl. 1): S304.
26. Meyer, J.-P., Adumeau, P., Lewis, J.S., and Zeglis, B.M. (2016). Click chemistry and radiochemistry: the rst 10 years. Bioconjug Chem 27 (12): 2791–2807. https://doi. org/10.1021/acs.bioconjchem.6b00561.
27. Allott, L., Da Pieve, C., Turton, D.R., and Dmith, G. (2017). A general [
18
F]AlF radiochemistry procedure on two automated synthesis modules. React. Chem. Eng. 2: 68–74.
28. Antuganov, D.O., Ryzhkova, D.V., Zykova, T.A. etal. (2018). Modication of automatic synthesis of [
18
F]Fluoromisonidazole on a GE TracerLAB Fx F-N synthesis module.
Radiochemistry 60: 45–50.
Chapter 13: Automated Synthesis Modules for PET Radiochemistry 451
29. Garcia-Arguello, S.F., Lopez-Lorenzo, B., and Ruiz-Cruces, R. (2019). Automated pro­duction of [
68
Ga]Ga-DOTANOC and [68Ga]Ga-PSMA-11 using a TRACERlab FXFN syn-
thesis module. J. Labelled Compd. Radiopharm. 62: 146–153.
30. Shao, X., Hockley, B.G., Hoareau, R. etal. (2011c). Fully automated preparation of [ choline and [
18
F]uoromethylcholine using TracerLab synthesis modules and facili-
11
C]
tated quality control using analytical HPLC. Apll. Radiat. Isot. 69: 403–409.
31. Shao, X. and Kilbourn, M.R. (2009). A simple modication of GE tracerlab FX C Pro for rapid sequential preparation of [
11
C]carfentanil and [11C]raclopride. Appl. Radiat. Isot.
67: 602–605.
32. Dahl, K., Garcia, A., Stephenson, N.A., and Vasdev, N. “In-loop”
18
F-uorination: a
proof-of-concept study. J. Labelled Compd. Radiopharm. 62: 292–297.
33. Lazari, M., Quinn, K.M., Claggett, S.B. etal. (2013). ELIXYS-a fully automated, three-
reactor high-pressure radiosynthesizer for development and routine production of
diverse PET tracers. EJNMMI Res. 3 (1): 52.
34. Lazari, M., Collins, J., Shen, B. etal. (2014). Fully automated production of diverse
18
F-labeled PET tracers on the ELIXYS multireactor radiosynthesizer without
hardware modication. J. Nucl. Med. Technol. 42: 203–210.
35. Waldmann, C.M., Gomez, A., Marchis, P. etal. (2017). An automated multidose syn­thesis of the potentiometric PET probe 4-[
18
([
F]FBnTP). Mol. Imaging Biol. 20 (2): 205–212.
18
F]Fluorobenzyl-triphenylphosphonium
36. Amaraesekera, B., Marchis, P.D., Bobinski, K.P. etal. (2013). High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers. Appl. Radiat. Isot. 78: 88–101.
37. Audrain, H. (2007). Positron emission tomography (PET) and microuidic devices: a breakthrough on the microscale? Angew. Chem. Int. Ed. 46: 1772–1775.
38. Awasthi, V., Watson, J., Gali, H. etal. (2014). A "dose on demand" biomarker gener­ator for automated production of [
18
F]F− and [18F]FDG. Appl. Radiat. Isot. 89: 167–175.
39. Bejot, R., Kersemans, V., Kelly, C. etal. (2010). Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [
18
F]FMISO as hypoxia-selective tracer for PET.
Nucl. Med. Biol. 37: 565–575.
40. Bouvet, V.R., Wuest, M., Wiebe, L.I., and Wuest, F. (2011). Synthesis of hypoxia imaging agent 1-(5-deoxy-5-uoro-α-D-arabinofuranosyl)-2-nitroimidazole using microuidic technology. Nucl. Med. Biol. 38: 235–245.
41. Bouvet, V., Wuest, M., Tam, P.H. etal. (2012). Microuidic technology: an economical and versatile approach for the synthesis of O-(2-[
18
F]uoroethyl)-L-tyrosine ([18F]
FET). Bioorg. Med. Chem. Lett. 22: 2291–2295.
42. Bouvet, V.R. and Wuest, F. (2013). Application of [
18
F]FDG in radiolabeling reactions
using microuidic technology. Lab Chip 13: 4290–4294.
43. Collier, T., Akula, M., and Kabalka, G. (2010). Microuidic synthesis of [
18
F]FMISO. J.
Nucl. Med. 51 (Suppl. 2): 1462.
44. Collier, T.L., Liang, S.H., Mann, J.J. etal. (2017). Microuidic radiosynthesis of [
18
F] FEMPT, a high anity PET radiotracer for imaging serotonin receptors. Beilstein J. Org. Chem. 13: 2922–2927.
452 Handbook of Radiopharmaceuticals
45. De Leonardis, F., Pascali, G., Salvadori, P.A. etal. (2010). Microuidic modules for
18F−
[
] activation- Towards an integrated modular lab on a chip for PET radiotracer
synthesis. Proc. MicroTAS 14: 1604–1606.
46. De Leonardis, F., Pascali, G., Salvadori, P.A. etal. (2011). On-chip pre-concentration and complexation of [
18
F]uoride ions via regenerable anion exchange particles for radiochemical synthesis of positron emission tomography tracers. J. Chromatogr. A 1218: 4714–4719.
47. Elizarov, A.M. (2009). Microreactors for radiopharmaceutical synthesis. Lab Chip 9: 1326 –1333.
48. Elizarov, A.M., van Dam, R.M., Shin, Y.S. etal. (2010). Design and optimization of coin-shaped microreactor chips for PET radiopharmaceutical synthesis. J. Nucl. Med. 51: 282–287.
49. Fortt, R. and Gee, A. (2013). Microuidics: a golden opportunity for positron emission tomography? Future Med. Chem. 5: 241–244.
50. Kealey, S., Plisson, C., Collier, T.L. etal. (2011). Microuidic reactions using [
11
C]carbon monoxide solutions for the synthesis of a positron emission tomography radiotracer. Org. Biomol. Chem. 9: 3313–3319.
51. Keng, P.Y., Chen, S., Ding, H. etal. (2012). Micro-chemical synthesis of molecular probes on an electronic microuidic device. Proc. Natl. Acad. Sci. U.S.A. 109: 690–695.
52. Keng, P.Y. and van Dam, R.M. (2015). Digital microuidics: a new paradigm for radio­chemistry. Mol. Imaging 14: 13–14.
53. Lu, S.Y. and Pike, V.W. (2007). Micro-reactors for PET tracer labeling. In: PET Chem­istry, Ernst Schering Research Foundation Workshop, vol. 62 (PET Chemistry) (eds. P.A. Schubiger, L. Lehmann and M. Friebe), 271–287.
54. Lee, C.C., Sui, G., Elizarov, A. etal. (2005). Multistep synthesis of a radiolabeled imaging probe using integrated microuidics. Science 310: 1793–1796.
55. Liu, K., Lepin, E.J., Wang, M.W. etal. (2011). Microuidic-based
18
F-labeling of biomol-
ecules for immuno-positron emission tomography. Mol. Imaging 10: 168–176.
56. Liu, Y., Tian, M., and Zhang, H. (2013). Microuidics for synthesis of peptide-based PET tracers. Biomed. Res. Int. 2013: 839683.
57. Liow, E., O’Brien, A., Luthra, S. etal. (2005). Preliminary studies of conducting high level production radiosyntheses using microuidic devices. J. Labelled Compd. Radio- pharm. 48: 28.
58. Lu, S. and Pike, V.W. (2010). Synthesis of [ reagent from [
18
F]uoride ion in a micro-reactor and at production scale. J. Fluorine
18
F]xenon diuoride as a radiolabeling
Chem. 131: 1032–1038.
59. Lu, S.Y., Watts, P., Chin, F.T. etal. (2004). Syntheses of
11
C- and 18F-labeled carboxylic
esters within a hydrodynamically driven micro-reactor. Lab Chip 4: 523–525.
60. Lu, S., Giamis, A.M., and Pike, V.W. (2009). Synthesis of [
18
F]fallypride in a micro-reac­tor: rapid optimization and multiple-production in small doses for micro-PET studies. Curr. Radiopharm. 2: 49–55.
61. Lu, S., Chun, J.H., and Pike, V.W. (2010). Fluorine-18 chemistry in micro-reactors. J. Labelled Compd. Radiopharm. 53: 234–238.
Chapter 13: Automated Synthesis Modules for PET Radiochemistry 453
62. Matesic, L., Kallinen, A., Greguric, I., and Pascali, G. (2017). Dose-on-demand produc-
tion of diverse
18
F-radiotracers for preclinical applications using a continuous ow
microuidic system. Nucl. Med. Biol. 52: 24–31.
63. Miller, P.W. (2009). Radiolabelling with short-lived PET (positron emission tomog­raphy) isotopes using microuidic reactors. J. Chem. Technol. Biotechnol. 84: 309–315.
64. Miller, P.W., de Mello, A.J., and Gee, A.D. (2010). Application of microuidics to the ultra-rapid preparation of uorine-18 labelled compounds. Curr. Radiopharm. 3: 254–262.
65. Miller, P.W., Audrain, H., Bender, D. etal. (2011). Rapid carbon-11 radiolabelling for PET using microuidics. Chem. Eur. J. 17: 460–463.
66. Pascali, G., Mazzone, G., Saccomanni, G. etal. (2010). Microuidic approach for fast labeling optimization and dose-on-demand implementation. Nucl. Med. Biol. 37: 547–555.
67. Pascali, G., Nannavecchia, G., Pitzianti, S., and Salvadori, P.A. (2011). Dose-on-demand
of diverse
18
F-uorocholine derivatives through a two-step microuidic approach.
Nucl. Med. Biol. 38: 637–644.
68. Pascali, G., Watts, P., and Salvadori, P.A. (2013). Microuidics in radiopharmaceutical chemistry. Nucl. Med. Biol. 40: 776–787.
69. Pascali, G. and Salvadori, P.A. (2016). Opportunities and challenges in the utilization of microuidic technologies to the production of radiopharmaceuticals. Chim. Oggi- Chem. Today 34: 28–32.
70. Rensch, C., Waengler, B., Yaroshenko, A. etal. (2012). Microuidic reactor geometries for radiolysis reduction in radiopharmaceuticals. Appl. Radiat. Isot. 70: 1691–1697.
71. Rensch, C., Jackson, A., Lindner, S. etal. (2013). Microuidics: a groundbreaking tech­nology for PET tracer production? Molecules 18: 7930–7956.
72. Selivanova, S.V., Mu, L., Ungersboeck, J. etal. (2012). Single-step radiouorination of peptides using continuous ow microreactor. Org. Biomol. Chem. 10: 3871–3874.
73. Simms, R.W., Causey, P.W., Weaver, D.M. etal. (2012). Preparation of technetium-99m bifunctional chelate complexes using a microuidic reactor: a comparative study with conventional and microwave labeling methods. J. Labelled Compd. Radiopharm. 55: 18–22.
74. Steel, C.J., O’Brien, A.T., Luthra, S.K., and Brady, F. (2007). Automated PET radiosyn­theses using microuidic devices. J. Labelled Compd. Radiopharm. 50: 308–311.
75. Ungersboeck, J., Philippe, C., Mien, L.K. etal. (2011). Microuidic preparation of [ FE@SUPPY and [
18
F]FE@SUPPY:2--comparison with conventional radiosyntheses.
18
F]
Nucl. Med. Biol. 38: 427–434.
76. Ungersboeck, J., Philippe, C., Haeusler, D. etal. (2012a). Optimization of [
11
C]DASB­synthesis: vessel-based and ow-through microreactor methods. Appl. Radiat. Isot. 70: 2615–2620.
77. Ungersboeck, J., Richter, S., Collier, L. etal. (2012b). Radiolabeling of [
18
F]altanse-
rin-a microuidic approach. Nucl. Med. Biol. 39: 1087–1092.
78. Voccia, S., Morelle, J.L., Aerts, J. etal. (2009). Mini-uidic chip for the total synthesis of PET tracers. J. Labelled Compd. Radiopharm. 52 (Suppl 1): S11.
454 Handbook of Radiopharmaceuticals